Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market is projected to register a CAGR of 21.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market, By Cancer Type (Lung, Breast, Colorectal, Prostrate, Stomach, Cervical, Leukemia and Others), Product & Service (Kits, Software & Services and Instruments), Technologies (Panels/Targeted Sequencing & Resequencing, Whole Exome Sequencing, Whole Genome Sequencing, RNA Sequencing and Other Sequencing Technologies), Workflow (NGS Sequencing, NGS Data Analysis and NGS Pre-Sequencing), Application (Screening, Companion Diagnostics and Others), End User (Pathology Labs, Hospitals, Oncology Centers and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Japan, Hong Kong, India, South Korea, Australia, Singapore, Thailand, Taiwan, New Zealand, Malaysia, Indonesia, Vietnam, Macao, Philippines and Rest of Asia-Pacific) Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of the Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market are:
• Increase in the incidences of cancer in the Asia-Pacific region.
• Increase in the adoption of genome-focused pharmacology for cancer treatment

Market Players:

The key market players for Asia-Pacific next generation sequencing (NGS) in cancer diagnostic market are listed below:

• Agilent Technologies, Inc.
• Twist Bioscience
• Millennium Science Pty Ltd
• Dow Biomedica Co.
• Spinco Biotech Pvt Ltd
• Quantabio
• Swift Biosciences Inc.
• ArcherDX, Inc.
• Premas Life Sciences
• TOMY DIGITAL BIOLOGY CO., LTD